Inc. (NASDAQ:INCR) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. 

On February 16, 2017, Dextera Surgical Inc. (“Dextera”) received from the staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) a letter (the “Delisting Notice”) notifying Dextera that its stockholders’ equity reported in its Form 10-Q for the period ended December 31, 2016, was less than $2.5 million, the minimum required by the continued listing requirements of Nasdaq listing rule 5550(b)(1). At that time, Dextera’s stockholders’ equity was reported at $0.4 million.

As provided in the Nasdaq rules, Dextera has 45 calendar days, or until April 3, 2017, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Delisting Notice to evidence compliance. Dextera intends to submit in a timely manner to the Staff a plan to continue listing on The Nasdaq Capital Market. There is no assurance that Nasdaq will accept the Company’s plan to satisfy the stockholders’ equity requirement. If the plan is not accepted or the Company is not granted an extension, Dextera will then consider actions appropriate to the circumstances, which may include applicable appeals to a Nasdaq Hearings Panel.

About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

Inc. (NASDAQ:INCR) Recent Trading Information

Inc. (NASDAQ:INCR) closed its last trading session up +0.30 at 54.50 with 312,885 shares trading hands.